Skip to content
mapperlab
← Dashboard
Stock

AMPH

Amphastar Pharmaceuticals, Inc.
Health CarePharmaceuticalsLatest close $175 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
5
27 funds tracked
Ever held
7
Current + past
New this quarter
0
Exited this quarter
0

Marquee-fund ownership over time

Aug 9, 2024Aug 14, 2024Feb 14, 2025May 15, 2025
Now
6

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies$43$17-60%
Two Sigma Investments$42$17-59%
AQR Capital Management$42$17-59%
Millennium Management$42$17-59%
D.E. Shaw$45$17-62%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Citadel Advisors 2× in & out—+0%
Point72 Asset Management→ $24-43%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Amphastar Pharmaceuticals, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
6
Filings · last 90d
22
Total on file
573
Recent SEC buffer
Most recent
Jun 3, 2026

30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 573 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Amphastar Pharmaceuticals, Inc.

Annual figures sourced directly from Amphastar Pharmaceuticals, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$719.89M
FY2025-2% YoY
Net income
$98.09M
FY2025-39% YoY
EPS (diluted)
$2.03
FY2025-34% YoY
Free cash flow(?)
$121.23M
FY2025-30% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Amphastar Pharmaceuticals, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Citadel AdvisorsQ1 2025Q2 2025$0.00—+0%
D.E. ShawQ4 2024open$45$17-62%
Citadel AdvisorsQ3 2024open$42$17-59%
Two Sigma InvestmentsQ3 2024open$42$17-59%
AQR Capital ManagementQ3 2024open$42$17-59%
Millennium ManagementQ3 2024open$42$17-59%
Point72 Asset ManagementQ3 2024Q2 2025$42$24-43%
Renaissance TechnologiesQ3 2024open$43$17-60%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.